Methods and compositions for reducing metastases

Abstract

The subject matter described herein is directed to methods of modifying the micro-environment of a target cell or The methods comprise systemically administering to a subject a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap in the target cell, wherein the trap is expressed in the target cell thereby modifying the micro-environment. Also described herein are methods of reducing metastasis of a cancer comprising, systemically administering to a subject suffering from the cancer, a composition comprising a vector, wherein the vector comprises a construct for the expression of a trap, wherein the trap is delivered to and then expressed in tissue susceptible to metastasis, wherein metastasis of the cancer to the tissue is reduced. Compositions for carrying out the methods are also described.

1 - 145 . (canceled) 
     
     
         146 . A polypeptide capable of binding CXCL12, wherein said polypeptide has at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 6, 7, 11, 12, and 16. 
     
     
         147 . The polypeptide of  claim 146 , wherein said polypeptide has at least 90% identity to a sequence selected from the group consisting of SEQ ID NOs: 1, 2, 6, 7, 11, and 12; and wherein the polypeptide comprises a VH region having three complementarity determining regions (CDRs). 
     
     
         148 . The polypeptide of  claim 147 , wherein the three CDRs are SEQ ID NOs: 3, 4, and 5. 
     
     
         149 . The polypeptide of  claim 148 , wherein the VH region has at least 90% identity to SEQ ID NO: 2. 
     
     
         150 . The polypeptide of  claim 148 , wherein the VH region is SEQ ID NO: 2. 
     
     
         151 . The polypeptide of  claim 148 , wherein the polypeptide has at least 90% identity to SEQ ID NO: 1. 
     
     
         152 . The polypeptide of  claim 147 , wherein the three CDRs are SEQ ID NOs: 8, 9, and 10. 
     
     
         153 . The polypeptide of  claim 152 , wherein the VH region has at least 90% identity to SEQ ID NO: 7. 
     
     
         154 . The polypeptide of  claim 152 , wherein the VH region is SEQ ID NO: 7. 
     
     
         155 . The polypeptide of  claim 152 , wherein the polypeptide has at least 90% identity to SEQ ID NO: 6. 
     
     
         156 . The polypeptide of  claim 147 , wherein the three CDRs are SEQ ID NOs: 13, 14, and 15. 
     
     
         157 . The polypeptide of  claim 156 , wherein the VH region has at least 90% identity to SEQ ID NO: 12. 
     
     
         158 . The polypeptide of  claim 156 , wherein the VH region is SEQ ID NO: 12. 
     
     
         159 . The polypeptide of  claim 156 , wherein the polypeptide has at least 90% identity to SEQ ID NO: 11. 
     
     
         160 . The polypeptide of  claim 146 , wherein said polypeptide has at least 90% identity to SEQ ID NO: 16, and said polypeptide comprises
 a) a V H  region, wherein the V H  region has at least 90% identity to SEQ ID NO: 17, and wherein the V H  region comprises three complementarity determining regions (CDRs); and   b) a V L  region, wherein the V L  region has at least 90% identity to SEQ ID NO: 18, and wherein the V L  region comprises three complementarity determining regions (CDRs).   
     
     
         161 . The polypeptide of  claim 160 , wherein the three CDRs of the V H  region are SEQ ID NOS: 19, 20, and 21, respectively, and the three CDRs of the V L  region are SEQ ID NOS: 22, 23, and 24, respectively. 
     
     
         162 . The polypeptide of  claim 161 , wherein the V L  region is SEQ ID NO: 18. 
     
     
         163 . The polypeptide of  claim 161 , wherein the V H  region is SEQ ID NO: 17 and the V L  region is SEQ ID NO: 18. 
     
     
         164 . The polypeptide of  claim 146 , wherein the polypeptide does not comprise a light chain or heavy chain constant region. 
     
     
         165 . A nucleic acid encoding the polypeptide of  claim 146 .